Free Trial
$100 Off Ends Tonight! MarketBeat All Access Returns to $249
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Save $100 Now
Claim MarketBeat All Access Sale Promotion

Healthcare and Medical Stocks List

This page shows information about the 50 largest healthcare and medical sector stocks including Eli Lilly and Company, Johnson & Johnson, AbbVie and UnitedHealth Group. Learn more about health care stocks.

Eli Lilly and Company stock logo

1. Eli Lilly and Company NYSE:LLY

$1,066.59 +1.59 (+0.15%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$1,065.00 -1.59 (-0.15%)
As of 05/22/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. More about Eli Lilly and Company

Pros of Eli Lilly and Company

  • The stock has received multiple upgrades from analysts, with recent target prices reaching as high as $1,400, indicating strong confidence in the company's future performance.
  • Eli Lilly and Co has a robust pipeline of innovative therapies, which positions the company well for future growth and revenue generation.
  • The current stock price is around $1,200, reflecting a significant increase over the past year, suggesting positive market sentiment and investor interest.

Cons of Eli Lilly and Company

  • Some analysts have issued lower target prices, with one report suggesting a target as low as $850, indicating potential concerns about future performance.
  • The stock has received a "Sell" rating from one analyst, which could signal caution for potential investors.
  • Market volatility and economic uncertainties could impact the pharmaceutical sector, potentially affecting Eli Lilly and Co's stock performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$1.00 trillion
P/E Ratio
37.89
Consensus Rating
Moderate Buy
Consensus Price Target
$1,220.37 (+14.4% Upside)
Volume
3.47 million shares
Average Volume
3.50 million shares
Today's Range
$1,047.07
$1,070.34
50-Day Range
$851.65
$1,066.59
52-Week Range
$623.78
$1,133.95
Dividend Yield
0.66%
Johnson & Johnson stock logo

2. Johnson & Johnson NYSE:JNJ

$234.67 +0.33 (+0.14%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$234.43 -0.25 (-0.10%)
As of 05/22/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. More about Johnson & Johnson

Pros of Johnson & Johnson

  • Recent analyst reports have set target prices for Johnson & Johnson as high as $285.00, indicating strong growth potential and a positive outlook from market experts.
  • The company has a robust oncology and urology pipeline, which is expected to grow, especially in light of recent surveys highlighting the need for better bladder cancer therapies.
  • Johnson & Johnson's mental health franchise has shown promising data with CAPLYTA, demonstrating favorable efficacy and safety compared to competing antipsychotics, which could enhance its market position.

Cons of Johnson & Johnson

  • Despite stable fundamentals, Johnson & Johnson's stock has declined about 3.5% since its last earnings report, indicating some investor caution.
  • There are ongoing legal challenges that could impact the company's reputation and financial performance, creating uncertainty for potential investors.
  • While the company has a strong pipeline, the immediate impact of recent developments may not significantly alter its earnings in the short term.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$564.91 billion
P/E Ratio
27.13
Consensus Rating
Moderate Buy
Consensus Price Target
$253.04 (+7.8% Upside)
Volume
5.46 million shares
Average Volume
7.58 million shares
Today's Range
$232.72
$235.50
50-Day Range
$221.17
$244.48
52-Week Range
$149.04
$251.71
Dividend Yield
2.24%
AbbVie stock logo

3. AbbVie NYSE:ABBV

$216.02 +0.32 (+0.15%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$216.39 +0.37 (+0.17%)
As of 05/22/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. More about AbbVie

Pros of AbbVie

  • The current stock price is around $213.77, which may present a buying opportunity for investors looking for growth in the pharmaceutical sector.
  • AbbVie has a strong market capitalization of approximately $377.69 billion, indicating a solid position in the industry and potential for stability.
  • Recent analyst ratings show a consensus of "Moderate Buy," with several analysts setting price targets above the current stock price, suggesting potential upside.

Cons of AbbVie

  • Recent insider selling, including significant transactions by executives, may raise concerns about the company's future performance and insider confidence.
  • The stock has a high P/E ratio of 105.31, which could indicate that it is overvalued compared to its earnings, making it a riskier investment.
  • AbbVie’s stock has experienced fluctuations, with a 52-week low of $180.25, suggesting volatility that could deter risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$381.65 billion
P/E Ratio
106.41
Consensus Rating
Moderate Buy
Consensus Price Target
$253.43 (+17.3% Upside)
Volume
5.41 million shares
Average Volume
6.29 million shares
Today's Range
$215.70
$220.01
50-Day Range
$197.24
$225.36
52-Week Range
$181.71
$244.81
Dividend Yield
3.21%
UnitedHealth Group stock logo

4. UnitedHealth Group NYSE:UNH

$388.42 -0.05 (-0.01%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$387.06 -1.35 (-0.35%)
As of 05/22/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. More about UnitedHealth Group

Pros of UnitedHealth Group

  • The company recently reported a revenue of $111.65 billion for the quarter, exceeding analyst estimates, indicating strong financial performance.
  • UnitedHealth Group has set its FY 2026 guidance at an earnings per share (EPS) of 18.250, suggesting confidence in future profitability.
  • The current stock price is around $355, which reflects a solid position in the market and potential for growth.

Cons of UnitedHealth Group

  • The recent exit of Berkshire Hathaway from its investment in UnitedHealth Group may raise concerns among other investors about the company's long-term prospects.
  • There are ongoing pressures from rising medical costs and changes in member mix, which could impact future earnings negatively.
  • Despite positive earnings, the stock has experienced volatility, which may deter risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$352.74 billion
P/E Ratio
29.34
Consensus Rating
Moderate Buy
Consensus Price Target
$387.57 (-0.2% Downside)
Volume
5.60 million shares
Average Volume
7.14 million shares
Today's Range
$381.01
$390.54
50-Day Range
$259.15
$400.69
52-Week Range
$234.60
$404.15
Dividend Yield
2.31%
Merck & Co., Inc. stock logo

5. Merck & Co., Inc. NYSE:MRK

$122.55 +0.14 (+0.11%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$122.52 -0.02 (-0.02%)
As of 05/22/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. More about Merck & Co., Inc.

Pros of Merck & Co., Inc.

  • The current stock price is around $112, reflecting a stable position in the market.
  • Merck has shown strong revenue growth, with quarterly revenue increasing compared to the same period last year, indicating robust business performance.
  • The company has a solid market capitalization of approximately $278 billion, suggesting it is a major player in the pharmaceutical industry.

Cons of Merck & Co., Inc.

  • The stock has experienced fluctuations, with a 52-week high of $125.14 and a low of $75.40, indicating potential volatility.
  • Merck's debt-to-equity ratio is 1.02, which suggests that the company has a significant amount of debt compared to its equity, potentially increasing financial risk.
  • Despite positive earnings, the price-to-earnings (P/E) ratio is relatively high at around 31.73, which may indicate that the stock is overvalued compared to its earnings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$302.67 billion
P/E Ratio
34.52
Consensus Rating
Moderate Buy
Consensus Price Target
$128.18 (+4.6% Upside)
Volume
14.75 million shares
Average Volume
8.53 million shares
Today's Range
$120.08
$122.66
50-Day Range
$109.33
$123.25
52-Week Range
$75.40
$125.14
Dividend Yield
2.78%
Novartis stock logo

6. Novartis NYSE:NVS

$152.14 +0.13 (+0.09%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$152.00 -0.14 (-0.09%)
As of 05/22/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More about Novartis

Pros of Novartis

  • The current stock price is around $146, which is significantly lower than its twelve-month high of $170.46, indicating potential for price appreciation.
  • Novartis AG has a strong market capitalization of approximately $272.84 billion, reflecting its stability and size in the pharmaceutical industry.
  • The company reported a solid net margin of over 25%, showcasing its ability to generate profit relative to its revenue.

Cons of Novartis

  • The company recently missed earnings expectations, reporting $1.99 earnings per share compared to the consensus estimate of $2.11, which may raise concerns about its growth prospects.
  • Quarterly revenue showed a slight decline of 0.9% year-over-year, indicating potential challenges in maintaining sales growth.
  • With a price-to-earnings (P/E) ratio of around 19.97, some investors may view the stock as overvalued compared to its earnings, which could deter investment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$290.31 billion
P/E Ratio
21.80
Consensus Rating
Hold
Consensus Price Target
$141.20 (-7.2% Downside)
Volume
1.41 million shares
Average Volume
1.35 million shares
Today's Range
$151.24
$152.55
50-Day Range
$142.99
$155.16
52-Week Range
$111.06
$170.46
Dividend Yield
2.03%
Novo Nordisk A/S stock logo

7. Novo Nordisk A/S NYSE:NVO

$44.91 -0.05 (-0.11%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$44.90 -0.01 (-0.03%)
As of 05/22/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More about Novo Nordisk A/S

Pros of Novo Nordisk A/S

  • The current stock price is around $46, which may present a buying opportunity for investors looking for growth in the pharmaceutical sector.
  • Recent reports indicate a surge in demand for the Wegovy pill, with over 2 million prescriptions since January, suggesting strong market potential and revenue growth.
  • Analysts have a consensus rating of "Hold" with a target price of approximately $65.56, indicating potential upside for investors.

Cons of Novo Nordisk A/S

  • Several analysts have downgraded their ratings recently, with some moving from "buy" to "hold," indicating a cautious outlook on the stock's performance.
  • The stock has experienced volatility, with a 12-month high of $81.44 and a low of $35.12, suggesting potential risks for investors.
  • Market sentiment may be affected by competitive pressures in the pharmaceutical industry, particularly in the diabetes and obesity treatment segments.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$200.52 billion
P/E Ratio
10.54
Consensus Rating
Hold
Consensus Price Target
$65.56 (+46.0% Upside)
Volume
10.77 million shares
Average Volume
17.38 million shares
Today's Range
$44.47
$45.18
50-Day Range
$35.28
$47.13
52-Week Range
$35.12
$81.44
Dividend Yield
3.89%
Amgen stock logo

8. Amgen NASDAQ:AMGN

$339.30 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$340.28 +0.98 (+0.29%)
As of 05/22/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. More about Amgen

Pros of Amgen

  • The current stock price is around $390, reflecting a strong market position and investor confidence in the company's future growth potential.
  • Amgen Inc. has received multiple upgrades from analysts, including a recent boost to a "strong-buy" rating, indicating positive sentiment and potential for price appreciation.
  • The company has a solid dividend yield of approximately 3.1%, providing investors with a steady income stream, which is particularly attractive in volatile markets.

Cons of Amgen

  • Despite recent upgrades, the consensus rating remains a "Hold," suggesting that some analysts are cautious about the stock's short-term performance.
  • Amgen Inc. has a relatively high dividend payout ratio of 70.15%, which may raise concerns about sustainability, especially if earnings do not grow as expected.
  • Recent price target adjustments by analysts indicate some uncertainty, with targets being cut from higher levels, which could signal potential challenges ahead.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$183.11 billion
P/E Ratio
23.61
Consensus Rating
Hold
Consensus Price Target
$355.19 (+4.7% Upside)
Volume
1.57 million shares
Average Volume
2.82 million shares
Today's Range
$338.40
$343.80
50-Day Range
$324.39
$367.79
52-Week Range
$267.83
$391.29
Dividend Yield
2.97%
Gilead Sciences stock logo

9. Gilead Sciences NASDAQ:GILD

$134.36 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$134.17 -0.19 (-0.14%)
As of 05/22/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More about Gilead Sciences

Pros of Gilead Sciences

  • Gilead Sciences, Inc. has received multiple recent upgrades from analysts, with target prices reaching as high as $165.00, indicating strong market confidence in the company's future performance.
  • The current stock price is around $129.58, which may present a buying opportunity for investors looking to enter at a lower price point compared to analysts' target prices.
  • With a market capitalization of approximately $160.88 billion, Gilead Sciences, Inc. is positioned as a major player in the biopharmaceutical industry, suggesting stability and growth potential.

Cons of Gilead Sciences

  • Insider selling has been observed, with significant shares sold by executives, which may raise concerns about their confidence in the company's future performance.
  • Some analysts have downgraded their ratings, indicating potential volatility and uncertainty in the stock's performance.
  • The company's debt-to-equity ratio of 0.89 suggests a moderate level of debt, which could impact financial flexibility and growth initiatives.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$166.82 billion
P/E Ratio
18.31
Consensus Rating
Moderate Buy
Consensus Price Target
$156.93 (+16.8% Upside)
Volume
5.97 million shares
Average Volume
6.24 million shares
Today's Range
$131.12
$134.52
50-Day Range
$127.75
$145.21
52-Week Range
$104.46
$157.29
Dividend Yield
2.44%
Thermo Fisher Scientific stock logo

10. Thermo Fisher Scientific NYSE:TMO

$448.55 +0.27 (+0.06%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$448.80 +0.25 (+0.05%)
As of 05/22/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More about Thermo Fisher Scientific

Pros of Thermo Fisher Scientific

  • The current stock price is around $615, reflecting a strong market position and investor confidence in the company's growth potential.
  • Recent upgrades from analysts, including a "strong-buy" rating from Jefferies Financial Group, indicate positive sentiment and potential for price appreciation.
  • Institutional ownership is high, with over 89% of shares held by institutional investors, suggesting strong backing and confidence from major financial entities.

Cons of Thermo Fisher Scientific

  • Recent reports indicate that some institutional investors, like Pinnacle Associates Ltd. and Applied Finance Capital Management LLC, have reduced their holdings, which may signal concerns about future performance.
  • Analysts have varied opinions on the stock, with some price targets being lowered, which could indicate potential volatility in the stock price.
  • The competitive landscape in the medical research sector is intense, and any significant advancements by competitors could impact Thermo Fisher Scientific Inc.'s market share.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$166.69 billion
P/E Ratio
24.66
Consensus Rating
Moderate Buy
Consensus Price Target
$616.10 (+37.4% Upside)
Volume
1.69 million shares
Average Volume
2.42 million shares
Today's Range
$444.41
$454.46
50-Day Range
$438.16
$531.69
52-Week Range
$385.46
$643.99
Dividend Yield
0.42%
Intuitive Surgical stock logo

11. Intuitive Surgical NASDAQ:ISRG

$438.10 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$437.33 -0.77 (-0.18%)
As of 05/22/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. More about Intuitive Surgical

Pros of Intuitive Surgical

  • The company recently reported strong quarterly earnings, with earnings per share significantly exceeding analysts' expectations, indicating robust financial health and operational efficiency.
  • Intuitive Surgical, Inc. has demonstrated impressive revenue growth, with a year-over-year increase of 23%, showcasing its expanding market presence and demand for its products.
  • The current stock price is around $421, which may present a buying opportunity for investors looking to enter at a lower price point compared to its 52-week high.

Cons of Intuitive Surgical

  • The stock has a high price-to-earnings (P/E) ratio, indicating that it may be overvalued compared to its earnings, which could deter value-focused investors.
  • Recent fluctuations in stock price have shown volatility, with a beta of 1.51, suggesting that the stock is more volatile than the market, which could pose risks for conservative investors.
  • Some analysts have lowered their price targets, indicating potential concerns about future growth or market conditions that could impact the company's performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$155.16 billion
P/E Ratio
53.10
Consensus Rating
Moderate Buy
Consensus Price Target
$579.33 (+32.2% Upside)
Volume
2.01 million shares
Average Volume
2.22 million shares
Today's Range
$434.77
$443.86
50-Day Range
$420.06
$483.62
52-Week Range
$417.74
$603.88
Dividend Yield
N/A
Abbott Laboratories stock logo

12. Abbott Laboratories NYSE:ABT

$87.42 +0.01 (+0.01%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$87.76 +0.34 (+0.39%)
As of 05/22/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More about Abbott Laboratories

Pros of Abbott Laboratories

  • The current stock price is around $92, reflecting a stable valuation in the healthcare sector.
  • Recent insider buying activity, including significant purchases by executives, indicates confidence in the company's future performance.
  • Abbott Laboratories has a diverse portfolio of medical products and services, which helps mitigate risks associated with reliance on a single product line.

Cons of Abbott Laboratories

  • Recent insider selling activity, although minor, may raise concerns about the executives' confidence in the stock's short-term performance.
  • The healthcare sector can be highly competitive, and Abbott Laboratories faces challenges from emerging technologies and new entrants.
  • Market volatility can impact stock prices, and recent fluctuations may deter risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$152.27 billion
P/E Ratio
24.49
Consensus Rating
Moderate Buy
Consensus Price Target
$119.43 (+36.6% Upside)
Volume
9.52 million shares
Average Volume
12.95 million shares
Today's Range
$87.05
$88.84
50-Day Range
$82.58
$110.80
52-Week Range
$81.97
$139.06
Dividend Yield
2.87%
Pfizer stock logo

13. Pfizer NYSE:PFE

$25.92 +0.02 (+0.07%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$25.91 -0.01 (-0.03%)
As of 05/22/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. More about Pfizer

Pros of Pfizer

  • Recent analyst upgrades have raised the price target for Pfizer Inc. to around $28.74, indicating potential for stock appreciation.
  • Pfizer Inc. is currently involved in a Phase 3 trial for a new endometrial cancer treatment, which could lead to significant revenue if successful.
  • Market sentiment has shown signs of improvement, with technical indicators suggesting a bullish trend for Pfizer Inc.'s stock.

Cons of Pfizer

  • Concerns about the sustainability of dividends have arisen due to a post-pandemic slowdown in revenue growth.
  • There is increasing pressure on Pfizer Inc. and other pharmaceutical companies from potential drug pricing reforms, which could impact profitability.
  • Analyst ratings remain mixed, with a significant number of analysts maintaining a "Hold" rating, suggesting limited upside potential.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$147.72 billion
P/E Ratio
19.79
Consensus Rating
Hold
Consensus Price Target
$28.61 (+10.4% Upside)
Volume
22.30 million shares
Average Volume
37.77 million shares
Today's Range
$25.76
$26.15
50-Day Range
$25.31
$28.56
52-Week Range
$22.88
$28.75
Dividend Yield
6.64%
Danaher stock logo

14. Danaher NYSE:DHR

$172.12 +0.12 (+0.07%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$172.24 +0.12 (+0.07%)
As of 05/22/2026 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. More about Danaher

Pros of Danaher

  • The current stock price is around $174, reflecting a stable market position and potential for growth.
  • Danaher Co. has a strong market capitalization of approximately $123.64 billion, indicating a robust financial foundation.
  • The company recently declared a quarterly dividend of $0.40 per share, which translates to an annualized yield of 1.0%, providing a return on investment for shareholders.

Cons of Danaher

  • The stock has experienced fluctuations, with a fifty-two week high of $242.80 and a low of $172.34, indicating potential volatility.
  • Danaher Co. has a relatively high price-to-earnings ratio compared to industry averages, which may suggest that the stock is overvalued.
  • Insider ownership is at 10.80%, which may raise concerns about the alignment of interests between management and shareholders.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$121.82 billion
P/E Ratio
33.29
Consensus Rating
Moderate Buy
Consensus Price Target
$238.65 (+38.7% Upside)
Volume
3.00 million shares
Average Volume
5.15 million shares
Today's Range
$171.14
$174.95
50-Day Range
$161.95
$198.58
52-Week Range
$160.93
$242.80
Dividend Yield
0.93%
Bristol Myers Squibb stock logo

15. Bristol Myers Squibb NYSE:BMY

$59.50 +0.05 (+0.08%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$59.40 -0.11 (-0.18%)
As of 05/22/2026 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More about Bristol Myers Squibb

Pros of Bristol Myers Squibb

  • The current stock price is around $56.10, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
  • Analysts have recently increased their earnings per share estimates for FY2026 to $6.31, indicating positive growth expectations for the company.
  • Bristol-Myers Squibb has a diverse portfolio of products, including recent advancements in treatments for various cancers and autoimmune diseases, which can drive future revenue growth.

Cons of Bristol Myers Squibb

  • Despite positive earnings projections, the stock has experienced fluctuations, with a 52-week high of $62.89 and a low of $42.52, indicating potential volatility.
  • Recent reports show that some analysts have downgraded their target prices, which could signal a lack of confidence in the stock's short-term performance.
  • The company has a relatively high debt-to-equity ratio of 2.10, which may raise concerns about its financial leverage and ability to manage debt effectively.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$121.51 billion
P/E Ratio
16.71
Consensus Rating
Hold
Consensus Price Target
$61.31 (+3.0% Upside)
Volume
6.49 million shares
Average Volume
10.45 million shares
Today's Range
$59.25
$60.25
50-Day Range
$55.62
$61.79
52-Week Range
$42.52
$62.89
Dividend Yield
4.23%
Stryker stock logo

16. Stryker NYSE:SYK

$316.39 -0.09 (-0.03%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$316.50 +0.11 (+0.03%)
As of 05/22/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. More about Stryker

Pros of Stryker

  • The current stock price is around $292, which may present a buying opportunity for investors looking for value in the medical technology sector.
  • Stryker Co. has a strong market presence with a market capitalization of approximately $111.88 billion, indicating stability and growth potential.
  • The company reported a quarterly revenue increase of 2.6% compared to the same quarter last year, showcasing its ability to grow even in challenging market conditions.

Cons of Stryker

  • The company recently missed earnings expectations, reporting $2.60 earnings per share (EPS) against a consensus estimate of $2.98, which may raise concerns about its profitability.
  • There has been insider selling, with a vice president selling over 5,000 shares, which could indicate a lack of confidence in the company's short-term prospects.
  • UBS Group has downgraded its price target for Stryker Co. from $400 to $380, reflecting a more cautious outlook from analysts.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$121.29 billion
P/E Ratio
36.62
Consensus Rating
Moderate Buy
Consensus Price Target
$395.48 (+25.0% Upside)
Volume
1.89 million shares
Average Volume
2.99 million shares
Today's Range
$312.43
$318.90
50-Day Range
$282.85
$349.89
52-Week Range
$281.00
$404.87
Dividend Yield
1.11%
CVS Health stock logo

17. CVS Health NYSE:CVS

$93.24 -0.02 (-0.02%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$93.61 +0.37 (+0.40%)
As of 05/22/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. More about CVS Health

Pros of CVS Health

  • CVS Health Co. recently reported strong earnings, with an EPS of $2.57, surpassing expectations and indicating robust financial health.
  • The company has shown a year-over-year revenue growth of 6.2%, reflecting its ability to expand and adapt in a competitive market.
  • CVS Health Co. has set a positive FY 2026 guidance with an EPS target between 7.300 and 7.500, suggesting confidence in future performance.

Cons of CVS Health

  • The dividend payout ratio is currently at 117.18%, which indicates that the company is paying out more in dividends than it earns, raising concerns about sustainability.
  • Insider selling activity has been noted, with significant shares sold by executives, which may signal a lack of confidence in the company's short-term prospects.
  • Despite positive revenue growth, the net margin is relatively low at 0.72%, suggesting that profitability could be a concern moving forward.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$118.97 billion
P/E Ratio
41.08
Consensus Rating
Moderate Buy
Consensus Price Target
$98.68 (+5.8% Upside)
Volume
4.84 million shares
Average Volume
9.04 million shares
Today's Range
$93.00
$94.15
50-Day Range
$69.98
$98.14
52-Week Range
$58.50
$98.43
Dividend Yield
2.85%
Vertex Pharmaceuticals stock logo

18. Vertex Pharmaceuticals NASDAQ:VRTX

$434.52 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$433.41 -1.11 (-0.26%)
As of 05/22/2026 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More about Vertex Pharmaceuticals

Pros of Vertex Pharmaceuticals

  • The company recently reported earnings per share of $4.47, exceeding analysts' expectations, which indicates strong financial performance and potential for future growth.
  • Vertex Pharmaceuticals Incorporated has a robust return on equity of 23.86%, suggesting effective management and profitability relative to shareholder equity.
  • With a net margin of 35.51%, the company demonstrates a strong ability to convert revenue into profit, which is attractive for investors seeking companies with solid financial health.

Cons of Vertex Pharmaceuticals

  • The stock has a P/E ratio of 25.89, which may indicate that it is overvalued compared to its earnings, potentially leading to a correction in stock price.
  • Despite recent growth, the company operates in a highly competitive biotechnology sector, which could impact its market share and profitability in the future.
  • Vertex Pharmaceuticals Incorporated's beta of 0.30 suggests lower volatility compared to the market, which may limit potential high returns for investors looking for aggressive growth.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$110.28 billion
P/E Ratio
25.77
Consensus Rating
Moderate Buy
Consensus Price Target
$555.17 (+27.8% Upside)
Volume
1.75 million shares
Average Volume
1.23 million shares
Today's Range
$432.96
$438.84
50-Day Range
$423.24
$478.13
52-Week Range
$362.50
$507.92
Dividend Yield
N/A
Sanofi stock logo

19. Sanofi NASDAQ:SNY

$44.29 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$44.44 +0.15 (+0.34%)
As of 05/22/2026 06:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More about Sanofi

Pros of Sanofi

  • Sanofi has recently raised its dividend by over 10%, indicating strong financial health and a commitment to returning value to shareholders.
  • The current stock price is around $43, which may present a buying opportunity for investors looking for value in the biopharma sector.
  • Analysts have issued a consensus target price of $51, suggesting potential upside from the current trading levels.

Cons of Sanofi

  • Recent downgrades from analysts, including a shift from "buy" to "neutral," may indicate concerns about the company's growth prospects.
  • Sanofi's stock has experienced fluctuations, with a 52-week low of $42.78, suggesting volatility that could deter risk-averse investors.
  • The company's debt-to-equity ratio is relatively low, which could imply limited leverage for growth opportunities compared to competitors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$108.02 billion
P/E Ratio
12.37
Consensus Rating
Hold
Consensus Price Target
$51.00 (+15.2% Upside)
Volume
2.76 million shares
Average Volume
2.68 million shares
Today's Range
$44.24
$45.12
50-Day Range
$42.42
$48.18
52-Week Range
$42.33
$53.03
Dividend Yield
3.98%
GSK stock logo

20. GSK NYSE:GSK

$51.38 +0.00 (+0.01%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$51.49 +0.11 (+0.21%)
As of 05/22/2026 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More about GSK

Pros of GSK

  • The current stock price is around $51.65, which may present a buying opportunity for investors looking for value in the pharmaceutical sector.
  • GSK plc has a solid dividend payout ratio of 38.8%, indicating that the company is generating sufficient earnings to cover its dividend payments, which can provide a steady income stream for investors.
  • Recent quarterly earnings showed a significant revenue increase of 6.2% year-over-year, suggesting strong operational performance and growth potential.

Cons of GSK

  • GSK plc has decreased its dividend payment by an average of 0.1% annually over the last three years, which may raise concerns about the company's long-term commitment to returning value to shareholders.
  • The company has a relatively high debt-to-equity ratio of 0.92, indicating that it relies on debt financing, which can be risky in volatile market conditions.
  • Despite recent revenue growth, the company's earnings per share (EPS) forecast for the current year is lower than previous expectations, which could signal potential challenges ahead.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$104.27 billion
P/E Ratio
13.35
Consensus Rating
Reduce
Consensus Price Target
$53.00 (+3.1% Upside)
Volume
3.15 million shares
Average Volume
4.18 million shares
Today's Range
$51.14
$51.80
50-Day Range
$49.66
$59.19
52-Week Range
$35.45
$61.69
Dividend Yield
3.53%
Medtronic stock logo

21. Medtronic NYSE:MDT

$78.66 +0.06 (+0.08%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$78.60 -0.06 (-0.08%)
As of 05/22/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More about Medtronic

Pros of Medtronic

  • The company recently reported earnings per share of $1.36, exceeding analyst expectations, which indicates strong financial performance and potential for growth.
  • Medtronic plc has a solid revenue stream, with quarterly revenue reaching approximately $9.02 billion, reflecting a year-over-year increase of about 5.8%.
  • The current stock price is around $97, which may present a buying opportunity for investors looking for value in the medical technology sector.

Cons of Medtronic

  • The company's earnings per share decreased from $1.38 in the previous year, indicating potential challenges in maintaining profitability.
  • Medtronic plc's dividend payout ratio is currently at 79.11%, which may raise concerns about sustainability, as a high payout ratio can limit reinvestment in growth opportunities.
  • Insider selling activity has been noted, with significant shares sold by executives, which could signal a lack of confidence in the company's short-term prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$100.99 billion
P/E Ratio
21.91
Consensus Rating
Moderate Buy
Consensus Price Target
$106.45 (+35.3% Upside)
Volume
7.05 million shares
Average Volume
10.01 million shares
Today's Range
$78.21
$79.25
50-Day Range
$74.56
$88.65
52-Week Range
$74.40
$106.33
Dividend Yield
3.63%
McKesson stock logo

22. McKesson NYSE:MCK

$765.30 -0.78 (-0.10%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$766.28 +0.97 (+0.13%)
As of 05/22/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. More about McKesson

Pros of McKesson

  • The current stock price is around $735, which reflects a strong market position and potential for growth.
  • Recent analyst upgrades, including Barclays raising their price target to $1,050, indicate positive market sentiment and confidence in the company's future performance.
  • McKesson Co. has a solid market capitalization of approximately $88 billion, suggesting stability and a strong presence in the healthcare sector.

Cons of McKesson

  • Insider sales have been significant, with over 3,264 shares sold recently, which may raise concerns about the executives' confidence in the company's short-term performance.
  • The stock has experienced fluctuations, with a one-year high of $999 and a low of $637, indicating volatility that could deter risk-averse investors.
  • Despite positive ratings, some analysts have lowered their price targets, which could suggest a more cautious outlook on the stock's immediate future.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$91.99 billion
P/E Ratio
19.89
Consensus Rating
Moderate Buy
Consensus Price Target
$968.87 (+26.6% Upside)
Volume
2.32 million shares
Average Volume
1.27 million shares
Today's Range
$759.30
$772.94
50-Day Range
$724.87
$943.88
52-Week Range
$637.00
$999.00
Dividend Yield
0.43%
HCA Healthcare stock logo

23. HCA Healthcare NYSE:HCA

$394.40 +0.33 (+0.08%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$395.84 +1.44 (+0.36%)
As of 05/22/2026 07:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. More about HCA Healthcare

Pros of HCA Healthcare

  • The current stock price is around $540, reflecting a strong market position and investor interest.
  • HCA Healthcare, Inc. reported a revenue increase of 4.3% compared to the same quarter last year, indicating growth in its operations.
  • Analysts have a consensus rating of "Moderate Buy" for HCA Healthcare, Inc., suggesting positive sentiment among investment professionals.

Cons of HCA Healthcare

  • The company missed analysts' consensus estimates for earnings per share by $0.04, which may raise concerns about its financial performance.
  • HCA Healthcare, Inc. has a negative return on equity of 295.93%, indicating potential inefficiencies in generating profit from shareholders' equity.
  • Recent downgrades from several investment firms, including a reduction in target prices, may reflect a cautious outlook on the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$87.49 billion
P/E Ratio
13.56
Consensus Rating
Moderate Buy
Consensus Price Target
$515.77 (+30.8% Upside)
Volume
1.11 million shares
Average Volume
1.56 million shares
Today's Range
$388.24
$397.55
50-Day Range
$392.39
$533.39
52-Week Range
$330.00
$556.52
Dividend Yield
0.79%
Boston Scientific stock logo

24. Boston Scientific NYSE:BSX

$57.71 -0.07 (-0.11%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$57.52 -0.19 (-0.33%)
As of 05/22/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More about Boston Scientific

Pros of Boston Scientific

  • The current stock price is around $55, which suggests a potential upside based on analysts' target prices.
  • Boston Scientific Co. has recently reported strong quarterly earnings, exceeding analysts' expectations, indicating robust financial health.
  • The company has a solid market capitalization, reflecting its significant presence in the medical device industry.

Cons of Boston Scientific

  • Recent price target reductions by several analysts may indicate concerns about the company's future growth potential.
  • The stock has experienced volatility, which could pose risks for investors looking for stable returns.
  • Despite positive earnings, the company has a relatively high price-to-earnings ratio, which may suggest that the stock is overvalued.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$85.77 billion
P/E Ratio
24.15
Consensus Rating
Moderate Buy
Consensus Price Target
$92.71 (+60.6% Upside)
Volume
11.74 million shares
Average Volume
17.85 million shares
Today's Range
$57.39
$58.51
50-Day Range
$52.67
$71.29
52-Week Range
$52.52
$109.50
Dividend Yield
N/A
Elevance Health stock logo

25. Elevance Health NYSE:ELV

$394.41 -0.28 (-0.07%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$394.60 +0.19 (+0.05%)
As of 05/22/2026 05:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Market Capitalization
$85.65 billion
P/E Ratio
16.78
Consensus Rating
Moderate Buy
Consensus Price Target
$399.32 (+1.2% Upside)
Volume
1.09 million shares
Average Volume
1.72 million shares
Today's Range
$392.02
$396.59
50-Day Range
$284.64
$402.32
52-Week Range
$273.71
$408.00
Dividend Yield
1.74%
Cigna Group stock logo

26. Cigna Group NYSE:CI

$286.06 -0.18 (-0.06%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$285.25 -0.81 (-0.28%)
As of 05/22/2026 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. More about Cigna Group

Pros of Cigna Group

  • The Cigna Group has shown a solid quarterly revenue increase of approximately 4.6% compared to the same quarter last year, indicating strong business performance and growth potential.
  • The current stock price is around $288.91, which reflects a stable valuation in the market, making it an attractive option for investors looking for growth in the health services sector.
  • The company has a favorable dividend yield of 2.1%, providing investors with a steady income stream, which is particularly appealing in a low-interest-rate environment.

Cons of Cigna Group

  • Insider selling has been notable, with a total of 205,904 shares sold recently, which may signal a lack of confidence among insiders regarding the company's future performance.
  • Despite the positive revenue growth, the stock has experienced fluctuations, and the recent insider transactions could indicate potential volatility ahead.
  • The company operates in a highly competitive health services market, which could impact its ability to maintain growth and profitability in the long term.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$75.67 billion
P/E Ratio
12.13
Consensus Rating
Moderate Buy
Consensus Price Target
$339.80 (+18.8% Upside)
Volume
1.44 million shares
Average Volume
1.73 million shares
Today's Range
$281.96
$286.56
50-Day Range
$257.97
$300.36
52-Week Range
$239.51
$338.89
Dividend Yield
2.18%
Regeneron Pharmaceuticals stock logo

27. Regeneron Pharmaceuticals NASDAQ:REGN

$638.88 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$634.44 -4.44 (-0.69%)
As of 05/22/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More about Regeneron Pharmaceuticals

Pros of Regeneron Pharmaceuticals

  • The current stock price is around $720, which may present a buying opportunity for investors looking for growth in the biotechnology sector.
  • Regeneron Pharmaceuticals, Inc. has a strong pipeline of biologic therapies, indicating potential for future revenue growth as new products are developed and commercialized.
  • The company recently announced a strategic collaboration with Parabilis Medicines, which could lead to significant milestone payments and royalties, enhancing its financial outlook.

Cons of Regeneron Pharmaceuticals

  • Recent setbacks in clinical trials, such as the phase 3 melanoma trial for fianlimab missing its main goal, have weakened confidence in some of the company's high-profile pipeline assets.
  • Analyst downgrades have occurred following the trial results, with several brokerages lowering their price targets, indicating a more cautious outlook on the stock's performance.
  • Despite a strong institutional presence, insider selling activity has been noted, which may raise concerns about the confidence of company executives in the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$67.54 billion
P/E Ratio
15.57
Consensus Rating
Moderate Buy
Consensus Price Target
$792.65 (+24.1% Upside)
Volume
994,824 shares
Average Volume
1.01 million shares
Today's Range
$632.72
$644.12
50-Day Range
$629.68
$777.25
52-Week Range
$476.49
$821.11
Dividend Yield
0.59%
Cencora stock logo

28. Cencora NYSE:COR

$275.01 +0.10 (+0.03%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$275.25 +0.24 (+0.09%)
As of 05/22/2026 07:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. More about Cencora

Pros of Cencora

  • The current stock price is around $254.90, which may present a buying opportunity given analysts' target prices suggesting significant upside potential.
  • Cencora, Inc. has received multiple "buy" ratings from analysts, indicating strong confidence in the company's future performance.
  • The company reported a year-over-year revenue increase of 5.5%, showcasing its ability to grow even in challenging market conditions.

Cons of Cencora

  • The company has a high debt-to-equity ratio of 3.62, indicating that it relies heavily on debt financing, which can be risky if market conditions change.
  • Despite positive revenue growth, the net margin is only 0.50%, suggesting that profitability may be a concern for investors looking for strong returns.
  • Analysts have varying target prices, with some estimates as low as $355.00, which could indicate uncertainty about the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$53.51 billion
P/E Ratio
21.09
Consensus Rating
Moderate Buy
Consensus Price Target
$380.25 (+38.3% Upside)
Volume
2.14 million shares
Average Volume
2.30 million shares
Today's Range
$270.88
$277.39
50-Day Range
$253.20
$352.39
52-Week Range
$244.82
$377.54
Dividend Yield
0.87%
Takeda Pharmaceutical stock logo

29. Takeda Pharmaceutical NYSE:TAK

$16.22 -0.03 (-0.16%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$16.13 -0.10 (-0.60%)
As of 05/22/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More about Takeda Pharmaceutical

Pros of Takeda Pharmaceutical

  • The current stock price is around $16.65, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
  • Takeda Pharmaceutical Company Limited has received a recent upgrade to a "strong-buy" rating, indicating positive sentiment from analysts regarding its future performance.
  • The company is launching a new transformation program aimed at achieving significant cost savings, which could enhance profitability and shareholder value in the coming years.

Cons of Takeda Pharmaceutical

  • The company reported a quarterly earnings miss, with earnings per share falling short of analyst expectations, which may raise concerns about its financial performance.
  • Takeda has a relatively high P/E ratio of 69.36, suggesting that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • Restructuring costs associated with the transformation program could impact short-term profitability, leading to potential volatility in the stock price.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$51.63 billion
P/E Ratio
41.60
Consensus Rating
Moderate Buy
Consensus Price Target
N/A
Volume
4.01 million shares
Average Volume
3.02 million shares
Today's Range
$16.07
$16.25
50-Day Range
$16.22
$18.77
52-Week Range
$12.99
$18.90
Dividend Yield
3.10%
argenex stock logo

30. argenex NASDAQ:ARGX

$806.46 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$807.39 +0.93 (+0.12%)
As of 05/22/2026 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More about argenex

Pros of argenex

  • The current stock price is around $805, reflecting strong market interest and confidence in the company's growth potential.
  • argenx SE has a robust pipeline of therapies targeting severe autoimmune diseases, with its lead product candidate, efgartigimod, showing promising results in treating conditions like myasthenia gravis.
  • Institutional investors and hedge funds own over 60% of the stock, indicating strong institutional confidence and support for the company's future performance.

Cons of argenex

  • The stock has experienced volatility, with a 1-year high of $934.62 and a low of $510.05, which may indicate uncertainty in the market regarding its future performance.
  • Despite strong growth potential, the company has a high price-to-earnings ratio, which could suggest that the stock is overvalued compared to its earnings.
  • Recent earnings reports show a net margin of 30.42%, which, while positive, may not be sustainable as the company invests heavily in research and development.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$49.90 billion
P/E Ratio
35.91
Consensus Rating
Moderate Buy
Consensus Price Target
$1,017.78 (+26.2% Upside)
Volume
171,192 shares
Average Volume
347,730 shares
Today's Range
$804.20
$827.37
50-Day Range
$663.93
$849.04
52-Week Range
$510.05
$934.62
Dividend Yield
N/A
Edwards Lifesciences stock logo

31. Edwards Lifesciences NYSE:EW

$85.93 +0.15 (+0.17%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$85.21 -0.72 (-0.84%)
As of 05/22/2026 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. More about Edwards Lifesciences

Pros of Edwards Lifesciences

  • The current stock price is around $82, reflecting a stable position in the market.
  • Edwards Lifesciences Co. reported a significant revenue increase of 16.7% compared to the same quarter last year, indicating strong growth potential.
  • The company has a solid net margin of 17.39%, showcasing effective cost management and profitability.

Cons of Edwards Lifesciences

  • The price-to-earnings (PE) ratio of 44.72 suggests that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • Insider selling activity has been notable, with significant shares sold recently, which may raise concerns about the company's future prospects.
  • The beta of 0.87 indicates that the stock is less volatile than the market, which might not appeal to investors seeking high-risk, high-reward opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$49.48 billion
P/E Ratio
45.71
Consensus Rating
Moderate Buy
Consensus Price Target
$95.65 (+11.3% Upside)
Volume
4.94 million shares
Average Volume
5.09 million shares
Today's Range
$83.12
$86.03
50-Day Range
$77.11
$85.93
52-Week Range
$72.30
$87.89
Dividend Yield
N/A
Cardinal Health stock logo

32. Cardinal Health NYSE:CAH

$200.42 -0.27 (-0.13%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$200.29 -0.13 (-0.06%)
As of 05/22/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. More about Cardinal Health

Pros of Cardinal Health

  • Analysts maintain a generally positive outlook, with several firms recently raising their price targets, indicating confidence in the company's future performance.
  • The current stock price is around $245, reflecting a stable position in the market despite recent fluctuations.
  • Cardinal Health, Inc. has reported strong earnings per share (EPS) performance, which can signal profitability and operational efficiency to investors.

Cons of Cardinal Health

  • Recent revenue figures missed expectations, which can lead to short-term selling pressure and indicate potential challenges in meeting market demands.
  • GAAP results showed a decline in operating earnings and EPS, primarily due to a significant goodwill impairment charge, which can raise concerns about the company's financial health.
  • The mixed nature of recent financial reports, with strong EPS but weak revenue, may create uncertainty and volatility, potentially deterring some investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$46.94 billion
P/E Ratio
30.64
Consensus Rating
Moderate Buy
Consensus Price Target
$241.80 (+20.6% Upside)
Volume
1.54 million shares
Average Volume
2.57 million shares
Today's Range
$199.69
$202.77
50-Day Range
$182.62
$219.24
52-Week Range
$137.75
$233.60
Dividend Yield
1.02%
IDEXX Laboratories stock logo

33. IDEXX Laboratories NASDAQ:IDXX

$559.37 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$557.80 -1.57 (-0.28%)
As of 05/22/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. More about IDEXX Laboratories

Pros of IDEXX Laboratories

  • The current stock price is around $528, which reflects a significant opportunity for potential growth given its historical high of nearly $770.
  • IDEXX Laboratories, Inc. reported a strong quarterly earnings performance, with earnings per share (EPS) of $3.47, exceeding analysts' expectations, indicating robust financial health.
  • The company has demonstrated impressive revenue growth, with a year-over-year increase of 14.3%, suggesting a strong demand for its diagnostic products and services.

Cons of IDEXX Laboratories

  • The stock has a relatively high price-to-earnings (P/E) ratio of around 40, which may suggest that the stock is overvalued compared to its earnings, potentially limiting upside for new investors.
  • Despite recent growth, the company faces competition in the diagnostic market, which could impact future revenue and market share.
  • The stock has shown volatility with a beta of 1.58, indicating that it may be more sensitive to market fluctuations, which could pose risks for conservative investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$44.12 billion
P/E Ratio
41.19
Consensus Rating
Moderate Buy
Consensus Price Target
$751.00 (+34.3% Upside)
Volume
465,964 shares
Average Volume
649,583 shares
Today's Range
$549.75
$562.30
50-Day Range
$528.68
$591.84
52-Week Range
$496.61
$769.98
Dividend Yield
N/A
Haleon stock logo

34. Haleon NYSE:HLN

$9.30 +0.01 (+0.15%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$9.26 -0.04 (-0.46%)
As of 05/22/2026 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. More about Haleon

Pros of Haleon

  • The stock price recently opened at approximately $9.09, showing potential for recovery and growth opportunities in the consumer healthcare sector.
  • Haleon plc has received multiple upgrades from analysts, including a "strong-buy" rating from Argus, indicating strong confidence in the company's future performance.
  • Institutional investors have significantly increased their stakes in Haleon plc, with notable increases from firms like Bank of America and Morgan Stanley, suggesting strong institutional confidence in the company's prospects.

Cons of Haleon

  • Deutsche Bank recently downgraded Haleon plc from a "hold" to a "sell" rating, which may indicate concerns about the company's short-term performance.
  • The stock has experienced volatility, with a recent gap down in price, which could signal instability and potential risks for investors.
  • Despite positive revenue figures, the company faces competition in the consumer healthcare market, which could impact its market share and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$41.30 billion
P/E Ratio
23.86
Consensus Rating
Moderate Buy
Consensus Price Target
$13.40 (+44.0% Upside)
Volume
6.95 million shares
Average Volume
9.54 million shares
Today's Range
$9.27
$9.36
50-Day Range
$8.91
$10.60
52-Week Range
$8.71
$11.42
Dividend Yield
2.72%
Becton, Dickinson and Company stock logo

35. Becton, Dickinson and Company NYSE:BDX

$147.76 +0.13 (+0.09%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$147.64 -0.13 (-0.09%)
As of 05/22/2026 05:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. More about Becton, Dickinson and Company

Pros of Becton, Dickinson and Company

  • The current stock price is around $154, which may present a buying opportunity given analysts' recent price target increases.
  • Becton, Dickinson and Company has raised its full-year adjusted EPS guidance, indicating strong financial performance and growth potential.
  • The company returned approximately $2.3 billion to shareholders recently, including significant share repurchases, which can enhance shareholder value.

Cons of Becton, Dickinson and Company

  • The company is currently facing an FDA warning letter related to its El Paso facility, which could impact its reputation and operational capabilities.
  • Despite recent price target increases, some analysts have downgraded their ratings, indicating mixed sentiment in the market.
  • There are concerns regarding the company's debt levels, as it ended the quarter with net leverage above its long-term target, which could limit financial flexibility.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$40.71 billion
P/E Ratio
37.41
Consensus Rating
Hold
Consensus Price Target
$184.86 (+25.1% Upside)
Volume
1.29 million shares
Average Volume
3.38 million shares
Today's Range
$145.64
$148.25
50-Day Range
$142.36
$161.64
52-Week Range
$127.59
$187.35
Dividend Yield
2.87%
Alnylam Pharmaceuticals stock logo

36. Alnylam Pharmaceuticals NASDAQ:ALNY

$297.45 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$298.91 +1.46 (+0.49%)
As of 05/22/2026 07:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. More about Alnylam Pharmaceuticals

Pros of Alnylam Pharmaceuticals

  • The current stock price is around $294, which reflects a recent increase of 2.8%, indicating positive market sentiment.
  • Alnylam Pharmaceuticals, Inc. has received multiple upgrades from analysts, with a significant number rating it as a "Buy," suggesting strong future performance potential.
  • Institutional investors hold a substantial 92.97% of the stock, indicating confidence from large financial entities in the company's future prospects.

Cons of Alnylam Pharmaceuticals

  • Insider selling has been notable, with executives selling over 21,000 shares recently, which may signal a lack of confidence in the stock's short-term performance.
  • The stock has experienced significant volatility, with a 52-week high of $495.55 and a low of $284.19, indicating potential risks for investors.
  • Analysts have varied opinions on the stock, with some cutting target prices, which could reflect uncertainty about the company's future earnings potential.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$39.71 billion
P/E Ratio
81.27
Consensus Rating
Moderate Buy
Consensus Price Target
$463.13 (+55.7% Upside)
Volume
681,280 shares
Average Volume
1.08 million shares
Today's Range
$294.99
$303.33
50-Day Range
$284.84
$339.41
52-Week Range
$284.19
$495.55
Dividend Yield
N/A
Teva Pharmaceutical Industries stock logo

37. Teva Pharmaceutical Industries NYSE:TEVA

$34.03 -0.04 (-0.10%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$34.08 +0.05 (+0.15%)
As of 05/22/2026 06:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Market Capitalization
$39.13 billion
P/E Ratio
25.59
Consensus Rating
Moderate Buy
Consensus Price Target
$41.78 (+22.7% Upside)
Volume
2.71 million shares
Average Volume
7.65 million shares
Today's Range
$34.02
$34.85
50-Day Range
$28.37
$36.36
52-Week Range
$14.99
$37.35
Dividend Yield
N/A
Humana stock logo

38. Humana NYSE:HUM

$307.79 -0.16 (-0.05%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$302.93 -4.86 (-1.58%)
As of 05/22/2026 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. More about Humana

Pros of Humana

  • The current stock price is around $304.95, which reflects a recent increase of 1.2%, indicating positive market sentiment.
  • Humana Inc. reported a strong quarterly earnings per share (EPS) of $10.31, surpassing analysts' expectations, which suggests robust financial performance.
  • The company has shown significant revenue growth, with a 23.5% increase compared to the same quarter last year, indicating strong demand for its services.

Cons of Humana

  • Recent earnings estimates for FY2026 and FY2027 have been cut, indicating potential challenges in maintaining profitability.
  • Concerns have been raised about a projected large loss in Q4 2026, which could signal financial instability ahead.
  • Despite positive sentiment, the company has a relatively low net margin of 0.82%, which may limit its ability to generate profits.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$36.95 billion
P/E Ratio
32.92
Consensus Rating
Hold
Consensus Price Target
$263.35 (-14.4% Downside)
Volume
677,907 shares
Average Volume
1.98 million shares
Today's Range
$302.00
$309.21
50-Day Range
$163.80
$309.85
52-Week Range
$163.11
$315.66
Dividend Yield
1.15%
Zoetis stock logo

39. Zoetis NYSE:ZTS

$81.26 -0.07 (-0.08%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$80.75 -0.50 (-0.62%)
As of 05/22/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. More about Zoetis

Pros of Zoetis

  • The current stock price is around $77.78, which may present a buying opportunity for investors looking for growth in the animal health sector.
  • Recent insider purchases indicate confidence in the company's future, with directors acquiring significant shares, suggesting they believe the stock is undervalued.
  • Zoetis Inc. has a strong market capitalization of approximately $32.61 billion, indicating a solid position in the industry and potential for stability and growth.

Cons of Zoetis

  • Recent analyst downgrades, including a reduction in target prices by firms like UBS Group, indicate a cautious outlook on the stock's near-term performance.
  • The company has a high debt-to-equity ratio of 2.80, which may raise concerns about financial leverage and the ability to manage debt effectively.
  • Insider ownership is relatively low at 0.22%, which may suggest a lack of alignment between management and shareholder interests.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$34.06 billion
P/E Ratio
13.48
Consensus Rating
Hold
Consensus Price Target
$133.92 (+64.8% Upside)
Volume
6.33 million shares
Average Volume
8.86 million shares
Today's Range
$80.13
$82.34
50-Day Range
$74.11
$122.69
52-Week Range
$72.38
$172.23
Dividend Yield
2.61%
BeOne Medicines stock logo

40. BeOne Medicines NASDAQ:ONC

$310.25 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$305.65 -4.60 (-1.48%)
As of 05/22/2026 06:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Market Capitalization
$34.04 billion
P/E Ratio
69.41
Consensus Rating
Moderate Buy
Consensus Price Target
$389.15 (+25.4% Upside)
Volume
190,918 shares
Average Volume
230,234 shares
Today's Range
$305.98
$310.74
50-Day Range
$274.73
$323.87
52-Week Range
$235.35
$385.22
Dividend Yield
N/A
Waters stock logo

41. Waters NYSE:WAT

$342.83 +0.46 (+0.13%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$343.54 +0.71 (+0.21%)
As of 05/22/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Further, the company provides thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.

Market Capitalization
$33.66 billion
P/E Ratio
43.56
Consensus Rating
Moderate Buy
Consensus Price Target
$396.00 (+15.5% Upside)
Volume
477,982 shares
Average Volume
1.19 million shares
Today's Range
$338.00
$346.57
50-Day Range
$283.58
$355.12
52-Week Range
$275.05
$414.15
Dividend Yield
N/A
Alcon stock logo

42. Alcon NYSE:ALC

$67.82 +0.04 (+0.05%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$67.80 -0.02 (-0.03%)
As of 05/22/2026 06:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alcon Inc researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. More about Alcon

Pros of Alcon

  • Recent analyst ratings have been positive, with multiple firms issuing buy ratings, indicating strong confidence in the company's future performance.
  • The median price target set by analysts is around $94.5, suggesting potential for significant upside from the current stock price.
  • Alcon Inc. has seen increased institutional interest, with numerous investors adding shares to their portfolios, which can indicate a positive outlook on the stock.

Cons of Alcon

  • There has been notable selling activity from institutional investors, with some large firms significantly reducing their holdings, which may signal a lack of confidence.
  • One member of Congress recently sold shares of Alcon Inc., which could raise concerns about insider sentiment regarding the stock's future performance.
  • The competitive landscape in the eye care industry is intense, with many companies vying for market share, which could impact Alcon Inc.'s growth potential.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.54 billion
P/E Ratio
40.85
Consensus Rating
Moderate Buy
Consensus Price Target
$85.12 (+25.5% Upside)
Volume
2.00 million shares
Average Volume
2.58 million shares
Today's Range
$67.60
$68.48
50-Day Range
$61.98
$81.35
52-Week Range
$61.83
$92.55
Dividend Yield
N/A
Agilent Technologies stock logo

43. Agilent Technologies NYSE:A

$115.01 +0.05 (+0.04%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$114.22 -0.79 (-0.69%)
As of 05/22/2026 06:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. More about Agilent Technologies

Pros of Agilent Technologies

  • The current stock price is around $114.84, which may present a buying opportunity for investors looking for growth in the medical research sector.
  • Agilent Technologies, Inc. reported a revenue increase of 7.0% compared to the same quarter last year, indicating strong business performance and potential for future growth.
  • The company has a solid return on equity of 24.49%, suggesting effective management and profitability, which can be attractive to investors seeking reliable returns.

Cons of Agilent Technologies

  • The company recently missed earnings expectations, reporting $1.36 EPS compared to the consensus estimate of $1.37, which may raise concerns about its short-term performance.
  • Agilent Technologies, Inc. has seen its stock price decline from a 12-month high of $160.27, which could indicate a downward trend that investors should be cautious of.
  • The company has a relatively high P/E ratio of 25.35, which may suggest that the stock is overvalued compared to its earnings, potentially deterring value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$32.50 billion
P/E Ratio
25.39
Consensus Rating
Buy
Consensus Price Target
$163.71 (+42.4% Upside)
Volume
2.04 million shares
Average Volume
2.13 million shares
Today's Range
$113.68
$116.36
50-Day Range
$110.35
$122.10
52-Week Range
$107.07
$160.27
Dividend Yield
0.89%
Revolution Medicines stock logo

44. Revolution Medicines NASDAQ:RVMD

$151.56 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$151.50 -0.06 (-0.04%)
As of 05/22/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Market Capitalization
$32.22 billion
P/E Ratio
N/A
Consensus Rating
Buy
Consensus Price Target
$111.35 (-26.5% Downside)
Volume
1.93 million shares
Average Volume
2.69 million shares
Today's Range
$151.44
$156.25
50-Day Range
$92.51
$153.73
52-Week Range
$34.00
$156.25
Dividend Yield
N/A
Royalty Pharma stock logo

45. Royalty Pharma NASDAQ:RPRX

$54.50 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$54.46 -0.05 (-0.08%)
As of 05/22/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. More about Royalty Pharma

Pros of Royalty Pharma

  • The current stock price is around $52.85, reflecting a strong market position and investor confidence in the company's future growth.
  • Royalty Pharma plc has received multiple upgrades from investment analysts, indicating positive sentiment and potential for price appreciation.
  • Institutional investors own over half of the company's stock, suggesting strong institutional confidence and stability in ownership.

Cons of Royalty Pharma

  • Insider selling has occurred recently, with significant shares sold, which may raise concerns about the company's short-term outlook.
  • The company's high P/E ratio suggests that the stock may be overvalued compared to its earnings, which could lead to price corrections.
  • Market volatility can impact the biopharmaceutical sector, and any adverse regulatory changes could affect Royalty Pharma's revenue streams.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$31.38 billion
P/E Ratio
37.08
Consensus Rating
Buy
Consensus Price Target
$53.71 (-1.4% Downside)
Volume
3.05 million shares
Average Volume
3.69 million shares
Today's Range
$53.69
$54.64
50-Day Range
$45.36
$54.50
52-Week Range
$32.15
$54.64
Dividend Yield
1.72%
ResMed stock logo

46. ResMed NYSE:RMD

$208.04 -0.02 (-0.01%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$208.05 +0.02 (+0.01%)
As of 05/22/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. More about ResMed

Pros of ResMed

  • The current stock price is around $202, which may present a buying opportunity for investors looking for value in the medical device sector.
  • ResMed Inc. reported a strong quarterly earnings performance, with earnings per share (EPS) of $2.86, exceeding analysts' expectations, indicating robust financial health.
  • The company has shown a year-over-year revenue growth of 10.8%, suggesting a positive trend in sales and market demand for its products.

Cons of ResMed

  • Insider selling has been observed, with executives selling shares worth over $4 million recently, which may raise concerns about their confidence in the company's future performance.
  • The stock has experienced fluctuations, with a 52-week high of $293.81 and a low of $198.61, indicating potential volatility that could deter risk-averse investors.
  • Despite strong earnings, the company's price-to-earnings (P/E) ratio of 19.48 suggests that the stock may be overvalued compared to its earnings, which could limit upside potential.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$30.31 billion
P/E Ratio
20.06
Consensus Rating
Moderate Buy
Consensus Price Target
$286.18 (+37.6% Upside)
Volume
1.10 million shares
Average Volume
1.50 million shares
Today's Range
$207.25
$211.06
50-Day Range
$198.87
$233.60
52-Week Range
$198.61
$293.81
Dividend Yield
1.15%
GE HealthCare Technologies stock logo

47. GE HealthCare Technologies NASDAQ:GEHC

$64.23 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$64.01 -0.22 (-0.35%)
As of 05/22/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. More about GE HealthCare Technologies

Pros of GE HealthCare Technologies

  • The company has recently combined its Imaging and Advanced Visualization Solutions into Advanced Imaging Solutions, which is expected to enhance operational efficiency and drive growth over time.
  • Insider buying activity has been noted, with key executives purchasing shares at around $60.45 and $59.92, indicating confidence in the company's future performance.
  • GE HealthCare Technologies Inc. has a diverse portfolio that includes advanced diagnostic imaging systems, which are critical in modern healthcare, potentially leading to sustained demand.

Cons of GE HealthCare Technologies

  • Recent guidance cuts have lowered the FY26 EPS forecast to between $4.80 and $5.00, which is below market expectations, indicating potential challenges ahead.
  • Margin pressures due to inflation and rising costs for components like chips and oil have been cited as significant concerns, which could impact profitability.
  • Analyst downgrades from firms like JPMorgan and Citigroup, with price targets reduced from $80 to $65, reflect lowered expectations and could lead to further stock price declines.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$29.22 billion
P/E Ratio
15.37
Consensus Rating
Moderate Buy
Consensus Price Target
$80.21 (+24.9% Upside)
Volume
3.18 million shares
Average Volume
7.01 million shares
Today's Range
$63.91
$65.10
50-Day Range
$59.49
$74.67
52-Week Range
$58.75
$89.77
Dividend Yield
0.22%
Centene stock logo

48. Centene NYSE:CNC

$59.15 +0.01 (+0.02%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$58.84 -0.31 (-0.52%)
As of 05/22/2026 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. More about Centene

Pros of Centene

  • Recent price target increases from analysts, including a significant boost to $68.00, suggest strong potential upside from the current stock price, which is around $54.44.
  • Centene Co. has received multiple "outperform" and "buy" ratings from various brokerages, indicating positive sentiment and confidence in the company's future performance.
  • The company operates in the healthcare sector, which is generally resilient and continues to grow, especially in government-sponsored programs like Medicaid and Medicare.

Cons of Centene

  • Some analysts have expressed concerns about execution, suggesting that the company needs to improve operational performance to realize its growth potential.
  • There is a lower consensus price target of around $42 from some brokerages, which could limit upside potential if this view gains traction among investors.
  • Despite recent price target increases, the overall sentiment remains mixed, with several analysts maintaining "hold" or "neutral" ratings, indicating caution.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$29.21 billion
P/E Ratio
N/A
Consensus Rating
Hold
Consensus Price Target
$56.94 (-3.7% Downside)
Volume
2.92 million shares
Average Volume
7.41 million shares
Today's Range
$58.11
$59.20
50-Day Range
$31.72
$59.34
52-Week Range
$25.08
$60.76
Dividend Yield
N/A
Natera stock logo

49. Natera NASDAQ:NTRA

$203.19 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$203.46 +0.28 (+0.14%)
As of 05/22/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Market Capitalization
$29.10 billion
P/E Ratio
N/A
Consensus Rating
Moderate Buy
Consensus Price Target
$256.60 (+26.3% Upside)
Volume
1.04 million shares
Average Volume
1.70 million shares
Today's Range
$202.26
$210.67
50-Day Range
$182.65
$219.82
52-Week Range
$131.81
$256.36
Dividend Yield
N/A
Biogen stock logo

50. Biogen NASDAQ:BIIB

$193.76 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$193.50 -0.26 (-0.13%)
As of 05/22/2026 07:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. More about Biogen

Pros of Biogen

  • The current stock price is around $190, indicating a potential upside based on recent analyst price targets.
  • Biogen Inc. has received multiple upgrades from analysts, with some raising their price targets, suggesting positive market sentiment.
  • The company has a strong focus on neurological and neurodegenerative diseases, which are areas of significant unmet medical need, potentially leading to high demand for its therapies.

Cons of Biogen

  • Recent adjustments to price targets by analysts, including a slight reduction from $201 to $200, may signal cautious sentiment in the market.
  • The company faces potential earnings headwinds due to recent transactions, which could impact profitability in the near term.
  • Despite positive earnings, some analysts have expressed concerns about constrained near-term growth, which could limit stock performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$28.61 billion
P/E Ratio
20.79
Consensus Rating
Moderate Buy
Consensus Price Target
$215.62 (+11.3% Upside)
Volume
892,915 shares
Average Volume
1.21 million shares
Today's Range
$190.01
$194.75
50-Day Range
$172.34
$204.53
52-Week Range
$121.05
$205.97
Dividend Yield
N/A